Buchumschlag

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
von: Pegah Golabi, et al.
Veröffentlicht: (2024)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
von: Sung Won Chung, et al.
Veröffentlicht: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
von: Wenjun Meng, et al.
Veröffentlicht: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
von: Victoria T. Kronsten, et al.
Veröffentlicht: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
von: Yaomin Wang, et al.
Veröffentlicht: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
von: Parminder Kaur, et al.
Veröffentlicht: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
von: Shusuke Kumazaki, et al.
Veröffentlicht: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
von: Vishnu Girish, et al.
Veröffentlicht: (2024)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
von: Julian Hercun, et al.
Veröffentlicht: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
von: Ann T. Ma, et al.
Veröffentlicht: (2024)

Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea
von: Saam Dilmaghani, et al.
Veröffentlicht: (2025)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
von: Shintaro Akiyama, et al.
Veröffentlicht: (2024)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
von: Gong Feng, et al.
Veröffentlicht: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
von: Lukas Hartl, et al.
Veröffentlicht: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis
von: Yusuf Yilmaz
Veröffentlicht: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
von: Tsz Hong Yiu, et al.
Veröffentlicht: (2024)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
von: Zhe‐Kun Xiong, et al.
Veröffentlicht: (2025)

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
von: Mohammad Shehab, et al.
Veröffentlicht: (2025)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
von: Naohiro Yasuura, et al.
Veröffentlicht: (2024)

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
von: Stefan Schreiber, et al.
Veröffentlicht: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
von: Maryam Alahmad, et al.
Veröffentlicht: (2024)

No value of non‐selective beta‐blockers after TIPS‐insertion
von: Anja Tiede, et al.
Veröffentlicht: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
von: Jiamei Wang, et al.
Veröffentlicht: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
von: Maria Buti, et al.
Veröffentlicht: (2024)

Editorial: ARFI‐based techniques are better than VCTE for diagnosing advanced fibrosis in severe obesity
von: Davide Roccarina, et al.
Veröffentlicht: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Faecal incontinence: Retentive, non‐retentive and when to suspect organic pathology
von: Carlo Di Lorenzo
Veröffentlicht: (2024)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
von: Wah‐Kheong Chan, et al.
Veröffentlicht: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
von: Richie Manikat, et al.
Veröffentlicht: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
von: Lana Bridi, et al.
Veröffentlicht: (2024)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
von: Daniela S. Allende, et al.
Veröffentlicht: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
von: Lana Bridi, et al.
Veröffentlicht: (2024)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
von: Maria Mironova, et al.
Veröffentlicht: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
von: Junbin Yan, et al.
Veröffentlicht: (2024)